This HTML5 document contains 121 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.3109/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q86657799
rdf:type
wikibase:Item
schema:description
tudományos cikk บทความทางวิทยาศาสตร์ научная статья 2015년 논문 2015年學術文章 article científic artikel ilmiah articol științific 2015年学术文章 scientific article published on 26 February 2015 videnskabelig artikel udgivet 26. februar 2015 artículu científicu מאמר מדעי vitskapeleg artikkel vedecký článok vědecký článek 2015年学术文章 ২৬ ফেব্রুয়ারি ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2015年の論文 2015年學術文章 2015年學術文章 мақолаи илмӣ artikulong pang-agham article scientifique bilimsel makale 2015 nî lūn-bûn научна статия scienca artikolo teaduslik artikkel tieteellinen artikkeli наукова стаття, опублікована в лютому 2015 artículo científico publicado en 2015 2015年學術文章 vitenskapelig artikkel სამეცნიერო სტატია articolo scientifico научни чланак scientific article published on 26 February 2015 wetenschappelijk artikel artigo científico artykuł naukowy artikull shkencor wissenschaftlicher Artikel επιστημονικό άρθρο 2015年學術文章 2015年学术文章 научни чланак scientific article published on 26 February 2015 2015年学术文章 article scientific مقالة علمية نشرت في 26 فبراير 2015 vetenskaplig artikel artigo científico naučni članak artigo científico bài báo khoa học 2015年学术文章 2015年学术文章
p:P577
wds:Q86657799-1F9A43D0-B420-41E6-9C40-FE59D60221B8
wdt:P577
2015-02-26T00:00:00Z
p:P2093
wds:Q86657799-9D569738-A5DE-4F60-A54C-DF0A2C52E872 wds:Q86657799-A09B299B-A9C1-48E9-9488-2072C8478BA9 wds:Q86657799-56A3F24F-B67C-43A4-AB60-97EF7E7E923A wds:Q86657799-52779661-748E-4A84-9278-630FF37165E5 wds:Q86657799-4907EF17-CA36-4F27-9090-0FA81E3A34D2 wds:Q86657799-26912EA2-4851-4687-B8BE-2C498430F0CE
wdt:P2093
Jonathan G Drachman Edmund Ng Robert Stuart Stephen M Ansell Andres Forero-Torres Bertrand Coiffier
rdfs:label
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,
skos:prefLabel
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,
schema:name
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,
p:P50
wds:Q86657799-02726AC3-1F83-4EFC-9608-6A201FC63E65 wds:Q86657799-5305AE13-31D4-4A8B-A54F-4CF2EDC03F94 wds:Q86657799-41EC1C75-57DB-4213-A710-5B2CC7845F20 wds:Q86657799-DE5DAB0F-85A9-4604-B46D-DBCD8AC0A4E7 wds:Q86657799-E93CDD96-7B2F-4111-98CF-177CC114426F
wdt:P50
wd:Q102148850 wd:Q93204621 wd:Q106561774 wd:Q57614428 wd:Q60545128
p:P1476
wds:Q86657799-A9A89640-D327-48F0-8C0E-F6FEE2C12CF4
wdt:P1476
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
p:P304
wds:Q86657799-4B45A9ED-DBFD-449B-B731-5DEEE0523FD0
wdt:P304
2569-2578
p:P31
wds:Q86657799-C36E8CE5-333E-4E59-B428-815793D3863D
wdt:P31
wd:Q13442814
p:P921
wds:Q86657799-2A5AA4E4-303B-46A6-8F6A-DB6F7E49EEE8 wds:Q86657799-39334B0A-E0AD-484A-8E97-426F2B0CC4B4 wds:Q86657799-22B8F022-6DF9-478D-BAC1-AE0B032EE8C8 wds:Q86657799-5C8360FB-BE24-4F27-A63D-E720F492B4B3 wds:Q86657799-A99DB890-2EDD-4E26-922F-E1C39816D8FF wds:Q86657799-762A65A1-A004-4863-9A53-3E6FF3E7F7D8 wds:Q86657799-EA7BE106-533D-4644-9D10-983A633B8237
wdt:P921
wd:Q415588 wd:Q418560 wd:Q18936 wd:Q418817 wd:Q2626074 wd:Q412323 wd:Q4833719
p:P698
wds:Q86657799-23A011E9-20AC-4FA2-A4C3-ABF95D9C0F30
wdtn:P698
n10:25651427
wdt:P698
25651427
p:P1433
wds:Q86657799-728B993D-5B05-409A-9951-A05C64025C86
wdt:P1433
wd:Q6534493
p:P433
wds:Q86657799-F02B6AD5-C3F6-4F8B-92F5-22995387C789
p:P478
wds:Q86657799-8E89FEB3-FE8C-416B-B0C1-8108F8F7BB53
wdt:P433
9
wdt:P478
56
p:P356
wds:Q86657799-410F7D64-6E53-4857-AFC2-8D386DD21404
wdtn:P356
n12:10428194.2015.1007504
wdt:P356
10.3109/10428194.2015.1007504